| Literature DB >> 29438698 |
Lai Man Natalie Wu1, Yaqi Deng1, Jincheng Wang1, Chuntao Zhao1, Jiajia Wang1, Rohit Rao1, Lingli Xu2, Wenhao Zhou2, Kwangmin Choi1, Tilat A Rizvi1, Marc Remke3, Joshua B Rubin4, Randy L Johnson5, Thomas J Carroll6, Anat O Stemmer-Rachamimov7, Jianqiang Wu1, Yi Zheng1, Mei Xin1, Nancy Ratner1, Q Richard Lu8.
Abstract
Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive Schwann cell (SC)-lineage-derived sarcomas. Molecular events driving SC-to-MPNST transformation are incompletely understood. Here, we show that human MPNSTs exhibit elevated HIPPO-TAZ/YAP expression, and that TAZ/YAP hyperactivity in SCs caused by Lats1/2 loss potently induces high-grade nerve-associated tumors with full penetrance. Lats1/2 deficiency reprograms SCs to a cancerous, progenitor-like phenotype and promotes hyperproliferation. Conversely, disruption of TAZ/YAP activity alleviates tumor burden in Lats1/2-deficient mice and inhibits human MPNST cell proliferation. Moreover, genome-wide profiling reveals that TAZ/YAP-TEAD1 directly activates oncogenic programs, including platelet-derived growth factor receptor (PDGFR) signaling. Co-targeting TAZ/YAP and PDGFR pathways inhibits tumor growth. Thus, our findings establish a previously unrecognized convergence between Lats1/2-TAZ/YAP signaling and MPNST pathogenesis, revealing potential therapeutic targets in these untreatable tumors.Entities:
Keywords: Lats1/2; MPNST; PDGF signaling; Schwann cells; TAZ; YAP; hippo signaling; murine models; peripheral nerve sheath tumor; tumor suppressor
Mesh:
Substances:
Year: 2018 PMID: 29438698 PMCID: PMC5813693 DOI: 10.1016/j.ccell.2018.01.005
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743